Mymetics Corp (MYMX)

[Work Harder]

The virosome formulations will incorporate and evaluate two different SARS-CoV-2 antigens, one full length stabilized S protein, for which Mymetics is collaborating with the group of Dr. Rogier Sanders at the Amsterdam Medical Center of the University of Amsterdam, the Netherlands, and the second is a receptor binding domain recombinant protein of SARS-CoV-2.

Do you see what the man (Dr Kempers) is trying to tell you b/c it isn't the first time we round about heard that

If the gal @ Baylor see's what she wants then we could be in a good place here

Any Hiv update could be telling, imho

https://investorshub.advfn.com/boards/read_msg.aspx?message_id=159243451

:}